Physician profile
Chad E Tisdale
NPI 1992031934
$8,676.87
in general payments reported to CMS, 2019-2025
20 companies · $2,762 in 2025
The $2,762 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $50.74 · 2021: $282 · 2022: $1,165 · 2023: $1,010 · 2024: $3,147 · 2025: $2,762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,008 · Travel and Lodging: $2,893 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,008.25 |
| Travel and Lodging | $2,892.53 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $4,039.66 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $1,083.38 | 2019-2025 | Cequa |
| Alcon Vision LLC | $807.02 | 2021-2025 | Hydrus Microstent, Tryptyr, Total30 |
| Bausch & Lomb Americas INC. | $580.36 | 2022-2025 | Miebo, Xiidra, Infuse |
| Oyster Point Pharma, INC. | $427.78 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $287.34 | 2024-2025 | Vevye |
| Coopervision INC. | $186.86 | 2021-2022 | |
| Abbvie INC. | $185.20 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Johnson & Johnson Surgical Vision, INC. | $147.04 | 2022 | |
| Mallinckrodt Hospital Products INC. | $144.46 | 2022-2023 | Acthar |
| Tarsus Pharmaceuticals, INC. | $138.54 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $131.43 | 2019-2022 | |
| Amgen INC. | $124.46 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.29 | 2019 | |
| Allergan, INC. | $98.48 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $84.22 | 2024 | Oxervate |
| Glaukos Corporation | $36.62 | 2022 | |
| Sight Sciences, INC. | $24.31 | 2022 | |
| Shire North American Group INC | $15.67 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Tisdale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.